Wound healing is a complex biological process that consists of hemostasis, inflammation, proliferation, and remodeling. Large numbers of cell types, including neutrophils, macrophages, lymphocytes, keratinocytes, fibroblasts, and endothelial cells, are involved in this process and multiple factors can cause impaired wound healing by affecting one or more phases of the process. The influences of these local and systemic factors are not mutually exclusive and single or multiple factors may play a role in any one or more individual phases, contributing to the overall outcome of the healing process

Scarring following wounding is a major medical problem.

Acute wounds are phylogenetically optimised for rapid healing under extreme conditions and a seemingly evolutionary response is to maximise the inflammatory response. This process ensures that wounds heal quickly and prevents further bleeding from minor trauma or septicaemia from a slowly healing or infected wound. However, massive inflammatory responses outcompete the body´s regenerative capacity and result in excessive scarring which interferes with the natural healing process.

Celericon provides novel solutions to improve tissue regeneration and to reduce scar formation by using Extracellular Vesicles.

Product Goals include the development of an off-the-shelf therapeutic based on EVs and the time-independent manufacturing and storage of the product  for on-demand application to

  1. improve and accelerate healing of bone fractures and defects,
  2. to improve healing of ruptured tendons and tissue interfaces,
  3. to provide immediate neuroprotective intervention in the acute phase of traumatic spinal cord injuries (SCI) and
  4. to reduce scar formation following implantations.